Gynecology

Friday, December 9, 2011


08:30-10:00
OPENING SESSION
Chairpersons J.H.Lang, China (Honorary Chairman)
C.Q. Zhou, China
G. Lu, China
Z.J. Chen, China
Z. Ben Rafael, Israel
08:30-08:35 Opening remarks
Experts views on where our field is heading
08:35-08:55 Stem Cells and Their Significance in Gynecology
C. De Geyter, Switzerland
08:55-09:15 Sperm fitness testing and experimental IVF on integrated Lab-on-a-Chip devices
J. Cheng, K. Mitchelson, China
09:15-10:00
WHEN WILL LAPAROSCOPY REPLACE ALMOST ALL LAPAROTOMIES?
Capsule Video-Laparoscopy is developing fast, covering an ever growing number of operations and disciplines. Prof. Nezhat, often referred to as a "Wizard" in Laparoscopy, will present his personal view, an odyssey of science technology and will explain where Video-Laparoscopy is heading and if this technology will ever put to rest all laparotomies, and in his words: "The objectives of the lecture are, to motivate the younger physicians, bring hope to their work and education and encouragement in their careers"
C.R. Nezhat, USA

10:00-10:20 Coffee break

10:20-11:50
HRT: WHERE ARE WE HEADING?
Capsule WHI has brought about a sharp decline in hormone replacement therapy (HRT/HT) in asymptomatic and symptomatic women. A key criticism of WHI is the age of the population selected, which is well above the critical age window where HT is still expected to prevent (if at all) cardiovascular disease (CVD.) Whether all (class effect) or only certain type of progesterone are to be blamed and whether estrogens are really carcinogenic is another controversial aspect of this discussion.
Chairpersons Yu Qi, China
R. Langer, USA
E. Peer, Israel
10:20-11:05
Debate: Is There Evidence for a HT Critical Window to Prevent Disease?
Proposition: HRT should be started early to have an effect
R. Langer, USA
Opposition: No evidence exists for the "critical window" theory
S. Skouby, Denmark
Discussion
11:05-11:30 The hormonal connection to breast cancer, from molecular biology to clinical implications. Are all progesterones the same?
E. Peer, Israel
11:30-11:50 The WHO defines estrogens as "Carcinogenic": Fact or fallacy?
A. Mueck, Germany
Objectives Upon completion of this session, the audience will learn:
  • About the "critical window", and what proof there is of its existence
  • Whether it is still customary to prescribe HT, and to whom?
  • If HT is "a must" in premature menopause
  • The place of androgens in HT

11:50-12:10 Poster viewing

12:10-13:40
POSTMENOPAUSAL OSTEOPOROSIS
Capsule The usual patients with low bone mineral density and fracture risk who are seen by a gynecologist are often younger than 70 years, while research on drugs is undertaken on women over this age
Chairpersons A. Mueck, Germany
X. Ruan, China
Yu Qi, China
12:10-12:55
Debate: Should we Treat Women with Low Bone Mineral Density Who are Younger than 70 Years, and How?
Proposition: Evidence for the effectiveness of drugs at this age is lacking, and treatment is not cost-effective
R. Langer, USA
Opposition: There is enough experience to manage these patients, but therapy should be individualized
S. Skouby, Denmark

New SERM's have a role in prevention of OP?
13:15-13:40 Denosumab, the horizon for future treatment of osteoporosis: Rank-L story
E. Peer, Israel
Objectives To acquire knowledge of the following:
  • Risk factors and prevalence of osteoporotic fractures in women over 70 years
  • FRAX index in this age group, DEXA indication
  • Older and newer methods to prevent fractures

13:40-14:30 Lunch break

14:30-16:00
WOMEN AND OVARIAN CANCER: FROM CONCEPTION TO DIAGNOSIS
Capsule Early diagnosis of ovarian cancer can improve prognosis!
Chairpersons R. Moore, USA
T. Levy, Israel
14:30-15:00 Ovarian cancer screening
T. Levy, Israel
15:00-15:30 Pelvic mass risk assessment: Who is at high risk for ovarian cancer?
R. Moore, USA 
15:30-16:00 Pelvic mass in pregnancy: When do we need to intervene?
C.O. Granai, USA 
Objectives To acquire knowledge of the following:
  • Screening strategies for women at high risk for ovarian cancer
  • When pelvic mass is suspected to be cancer
  • Treatment of pelvic mass during pregnancy

16:00-16:30 Coffee break

16:30-18:00
FAMILY PLANNING
Capsule The field of family planning is constantly evolving in an effort to provide the right solution to most women and situations with minimal risks. What are the risks and how can we minimize them?
Chairpersons E. Peer, Israel
S. Skouby, Denmark
16:30-16:55 Hormonal contraception: Obesity and diabetes
S. Skouby, Denmark
16:55-17:15 Advantages of medicated IUD over non medicated in nulliparous women
A. Ber, Israel
17:15-17:40 Efficacy of LNG as an emergency contraceptive: A phase 4 trial
L.N. Cheng, China
17:40-18:00 LARC long acting reversible contraception: An update
S. Skouby, Denmark (TBC)
Objectives To acquire knowledge of the following:
  • Risk of OC's
  • IUS to nulliparous
  • Emergency Contraception
  • LARC
18:30-19:45 Special entertaining performance of “Snakes, Bugs and Us”
By “Skip” Granai, MD, USA



Saturday, December 10, 2011


08:30-10:00
COSMETIC GENITAL SURGERY
Capsule The reasons for the current surge in popularity of cosmetic genital surgery are not completely understood. Are they related to the surge in availability? To new methods and technologies that were introduced? To a real need or to a good marketing strategy? What are the methods, who are the patients, what are the perils and who should provide the services?
Chairperson A. Ostrzenski, USA
08:30-09:00 Deceptive and unethical procedures in cosmetic-plastic gynecology: Difficulties in identifying and eliminating them from the practice
T. Hailparn, USA
09:00-09:30 Progress in cosmetic-plastic gynecology: New surgical interventions, combine gynecologic and general cosmetic-plastic operations, and natural or synthetic fillers
M.N. Scheinberg, USA
09:30-10:00 Cosmetic-plastic gynecology: Complications and how to avoid them
A. Ostrzenski, USA
Objectives Anything you wanted to ask about cosmetic genital surgery and never dared to ask...

10:00-10:20 Coffee break

10:20-11:50
CONTROVERSIES IN THE TREATMENT OF MALIGNANCIES
Capsule Are there new aggressive procedures coupled with better survival rates? Expert opinion on a variety of clinical dilemmas in oncology
Chairperson C.O. Granai, USA
Discussants R. Moore, USA
T. Levy, Israel
T.H. Cheung, Hong Kong
S. Wilailak, Thailand
Surgery
  • Oophonectomy at hysterectomy: Is there a cut off age?
  • Should Low Malignant Potential tumors be surgically staged?
  • Lymphadenectomy for early stage endometrial cancer?
  • Lymphadenectomy for ovarian CA: Is it really necessary?
  • Aggressive cytoreductive surgery should be the first step in the management of ovarian cancer?
  • Surgery or primary chemo-radation for stage 1B2 cervical cancer?

Therapy
  • Adjuvant chemotherapy for ovarian malignant tumors of low potential
  • Neo-adjuvant chemotherapy for advanced-stage ovarian cancer and cervical cancer
  • Platinum-sensitive relapse ovarian CA outcome and quality of life?
  • Intraperitoneal chemotherapy in ovarian cancer

11:50-12:10 Poster viewing

12:10-13:40
ENDOSCOPY
Supported by unrestricted grant from Karl Storz GMBA
Capsule Should we continue to expand on indications for endoscopy?
Chairpersons T. Levy, Israel
C.R. Nezha, USA
R. Campo, Belgium
12:10-12:40 Trophy's choice? New generation of Hysteroscope
R. Campo, Belgium
12:40-13:10 Endometriosis of bowel, bladder, ureter, diaphragm, lumps and liver
C.R. Nezhat, USA
13:10-13:40 A new approach to the diagnosis of adenomyosis “Hysteroscopic exploration of the sub endometrial myometrium"
R. Campo, Belgium
Objectives To acquire knowledge of the following:
  • Surgical treatment of endometriosis
  • Introduction to Trophy’s choice
  • The place of hysteroscopy in the management of infertility
  • Diagnosis of adenomyosis

13:40-14:30 Lunch break

14:30-16:00
OPERATIVE PROCEDURES: TRICKS OF THE TRADE
Capsule Results of surgery depend on choosing the right procedure for the right patient, and recognizing the pitfalls and risks of the operation. Good results also depend on a meticulous technique. How can all these be improved?
Chairperson R. Campo, Belgium
14:30-14:55 Pain, infertility, pregnancy and endometriosis: Ancient conditions, ancient correlations and their ancient treatment
C.R. Nezhat, USA
14:55-15:15 Cosmetic-Plastic Gynecology: Controversy and progress
A. Ostrzenski, USA
15:15-15:40 Intra uterine adhesions (IUA) "Prevention and Treatment" a major challenge
R. Campo, Belgium
15:40-16:00 Mesh vs. non-mesh reconstruction for urinary incontinence
D. Dodero, Italy
Objectives Upon completion of this session, the audience will learn:
  • Where we are in containing endometriosis pain?
  • The new surge in popularity of cosmetic genital surgery
  • Withstanding the challenge of IUA
  • To mesh or not to mesh, this is the question!

16:00-16:30 Coffee break

16:30-18:00
CERVICAL CANCER AND HUMAN PAPILLOMA VIRUS (HPV)
Capsule Does vaccination mark the end of cervical cancer?
Chairperson C.P. Zou, China
Discussants R. Moore, USA
T. Levy, Israel
S. Wilailak, Thailand
T.H. Cheung, Hong Kong
Hot Controversies - Expert Opinions on:
  1. The difference between quadrivalent or bivalent HPV vaccine
  2. The efficacy of vaccination in adolescents and women over 30 years of age
  3. For how long does immunization provide immunity? Booster after 10 years?
  4. Whether current knowledge implies immunization against cancer, or merely precancerous stages?
  5. Is there concern that migration to other types of HPV will become the main cause of HPV-related cervical cancer?
  6. Should males be vaccinated?
  7. Is the Pap smear obsolete in immunized patients?
  8. Do we still need HPV-DNA typing?
  9. Routine inclusion of colposcopy in a pelvic examination. If so, how often?



Sunday, December 11, 2011



08:30-10:00
HORMONE THERAPY (HT) AND CANCER RISK
Capsule The fear of cancer still dominates the decisions of physicians and patients regarding initiation and continuation of HT
Chairpersons S. Skouby, Denmark
E. Peer, Israel
10:30-11:30
Debate:
Proposition: Breast cancer risk is related to the recommended HT dose and regimen!
A. Mueck, Germany
Opposition: It is impossible to predict women in whom HT will not increase the risk for breast cancer, and in any event it is unrelated to the dose and regimen!
R. Langer, USA
Discussion
09:30-10:00 Breast cancer risk and hormone replacement therapy: Is the choice of the progestogens important?
X. Ruan, China
Objectives Upon completion of this session, the audience will acquire knowledge:
  • What risks are associated with progesterone?
  • Risk and prevention of HT associated breast cancer

10:20-11:50
ENDOMETRIOSIS: WHAT IS THE BEST TREATMENT FOR INFERTILE PATIENTS?

(in Hall A)